Centessa Pharmaceuticals
MA - BostonPharmaceutical
Focus: Centessa Pharmaceuticals is an umbrella company that acquires and develops drug candidates, with a primary focus on neurology-related therapeutics. The company was acquired by Eli Lilly in May 2026 for $7.8 billion, signaling strong validation of its pipeline and strategy.
Profile data last refreshed 9h ago · AI intelligence enriched 3w ago
Open Jobs
11+2 this month
Stable — net +2 jobs in 30d
5 added, 3 removed. Backfill posture.
Should You Work at Centessa Pharmaceuticals?
AI assessmentA compelling opportunity for early-to-mid career scientists and operations professionals seeking pipeline depth and Eli Lilly's resources, but limited visibility into independent financial health and organizational growth trajectory.
Why Work Here
- Access to a diverse, multi-indication pipeline with 17 active trials spanning Phase 1–3, including Phase 3 programs in kidney disease (Lixivaptan) and hemophilia (SerpinPC) with near-term catalysts.
Data completeness
4/9 — Basic
Company HealthStrong
Pipeline
Late-stage
4 Phase 3+
LOE Risk
Protected
No near-term cliffs
Hiring
Stable
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Pipeline & Clinical Trials
No Intervention
Hemophilia aClinical Trials (1)
NCT05605678Hemophilia Non-Interventional Study Prior to SerpinPC Intervention (PRESent-5)
N/AHelp build intelligence for Centessa Pharmaceuticals
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.